Wyeth

Cebix Incorporated

Biogen Idec Ma Inc.

Janssen Sciences Ireland Uc

Janssen Alzheimer Immunotherapy

Cebix Ab

Biogen Ma Inc.

Elan Pharmaceuticals, Inc.

James Callaway

David J Burke

Christopher Phillips

Ivan Lieberburg

Barbara Horsey O'Connor

Michael Grundman

Sherwood Russ Lehrman

Shaun E Buckley

John Wahren

Sheri Barrack

Michelle Mazzoni

Lioudmila Tchistiakova

Davinder Gill

Angela Widom

Jack Steven Jacobsen

Karin Ekberg

Ronald Black

Lars Ekman

Keith M Gregg

Wagner Marcelo Zago

Gene G Kinney

Howard Foyt

Mark Daniels

Manuel J Buttini

Barbara Horsey O'connor

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Immunoglobulin formulation and method of preparation thereof

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Immunotherapy regimes dependent on ApoE status

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Use of tau to monitor immunotherapy

The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.

Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.

Pegylated C-peptide

Method for treating multiple sclerosis and crohn's disease

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A&#x3b2;. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.

Treatment of amyloidogenic diseases

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A&#x3b2;. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.

Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Methods and kits for preventing hypoglycemia

Growing community of inventors

San Diego, CA, United States of America

James Callaway